Anti-FAAH1 antibody [EPR7549]

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary

Fatty acid amide hydrolase 1 (FAAH1) often referred to simply as FAAH is an enzyme that plays a critical role in the degradation of fatty acid amides such as anandamide in the body. This enzyme weighing approximately 63 kDa is a part of the amidase signature family and is characterized by its amidase hydrolase activity. FAAH1 is predominantly expressed in the nervous system liver and gastrointestinal tract where it hydrolyses amide bonds facilitating the termination of signaling pathways initiated by neurotransmitter-like fatty acid amides.

Biological function summary

FAAH1 is essential for maintaining homeostasis by modulating levels of bioactive lipids. It exerts control over endocannabinoid signaling by breaking down anandamide a lipid derivative functioning as a neurotransmitter. FAAH1 does not act as part of a larger protein complex. Instead it operates alone to regulate the duration and intensity of signaling rather than relying on direct interactions within a complex. The enzyme's function impacts the neurochemical milieu in tissues where it is actively expressed thereby affecting mood pain sensation and more.

Pathways

FAAH1 has a significant role in the endocannabinoid signaling pathway and fatty acid metabolism. Within these pathways it modulates signaling by hydrolysing bioactive amides like anandamide influencing overall lipid signaling. FAAH1 activities intersect with several other proteins such as cannabinoid receptors which bind the substrates that FAAH1 eventually degrades. These interactions are vital in controlling signal transduction processes that regulate physiological responses including stress and analgesia.

Associated diseases and disorders

FAAH1 has been implicated in conditions like chronic pain and anxiety disorders. Altered FAAH1 function or expression can lead to dysregulation of endocannabinoid signaling contributing to the pathophysiology of these conditions. The enzyme's modulation of anandamide levels connects it to proteins such as CB1 and CB2 cannabinoid receptors which mediate the effects of endocannabinoids in neurological and psychiatric disorders. Research into FAAH1 inhibitors as therapeutic agents highlights its importance in potential treatments for managing pain and anxiety.